

# **BIOCON GROUP**

## **FINANCIALS**

**9M FY 2007 vs 9M FY 2006**

## **FACT SHEET**

**BIOCON LIMITED (CONSOLIDATED)**
**PROFIT & LOSS STATEMENT**
*(Rs Crores)*

Particulars	9M FY 2007	9M FY 2006	Variance 9M FY 07 Vs 9M FY 06
<b><u>INCOME</u></b>			
Sales-Biopharmaceuticals	524	445	18%
Sales- Enzymes	68	60	13%
Contract research and licensing fees	116	70	66%
<b>Total Sales</b>	<b>708</b>	<b>575</b>	<b>23%</b>
Other income	2	3	
<b>Total Income / Revenues</b>	<b>710</b>	<b>578</b>	<b>23%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power Costs	373	311	20%
Staff costs	66	47	41%
Other expenses	71	47	50%
<b>Manufacturing, staff &amp; other exps</b>	<b>510</b>	<b>405</b>	<b>26%</b>
<b>PBDIT /EBIDTA</b>	<b>200</b>	<b>173</b>	<b>16%</b>
Interest and finance charges	6	1	
<b>PBDT</b>	<b>194</b>	<b>172</b>	<b>13%</b>
Depreciation	47	22	
<b>PBT</b>	<b>147</b>	<b>150</b>	<b>-2%</b>
Taxes	10	25	
<b>PROFIT FOR THE PERIOD</b>	<b>137</b>	<b>125</b>	<b>10%</b>
Add/(less): Minority interest	3	1	
<b>PAT</b>	<b>140</b>	<b>126</b>	<b>11%</b>
<b>EPS on issued capital (Rs)</b>	<b>14.0</b>	<b>12.6</b>	<b>11%</b>

*Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers*

<b>BIOCON LIMITED (CONSOLIDATED)</b>		
<b>BALANCE SHEET</b>		<i>(Rs. crores)</i>
<b>Particulars</b>	<b>As at 31-Dec-06</b>	<b>As at 31-Mar-06</b>
<b><u>SOURCES OF FUNDS</u></b>		
Share Capital	50	50
Reserves & Surplus	984	838
<b>Total Shareholder's Funds</b>	<b>1,034</b>	<b>888</b>
<b>Minority interest</b>	<b>3</b>	<b>3</b>
<b>Deferred Tax Liability</b>	<b>33</b>	<b>30</b>
Secured Loans	127	68
Unsecured Loans	46	37
<b>Total Loan Funds</b>	<b>173</b>	<b>105</b>
<b>Total</b>	<b>1,243</b>	<b>1,026</b>
<b><u>APPLICATION OF FUNDS</u></b>		
<b>Fixed Assets (Net)</b>	882	827
<b>Intangible Assets</b>	52	-
<b>Investments</b>	81	100
Inventories	170	110
Sundry debtors	253	224
Cash and bank balances	10	2
Loans and advances	31	24
<b>Total Current Assets, Loans &amp; Advances</b>	<b>464</b>	<b>360</b>
<b>Less: Current liabilities and provisions</b>	<b>236</b>	<b>261</b>
<b>Net Current assets</b>	<b>228</b>	<b>99</b>
<b>Total</b>	<b>1,243</b>	<b>1,026</b>

<b>BIOCON LIMITED (CONSOLIDATED)</b>		
<b>STATEMENT OF CASH FLOWS</b>		<i>(Rs. crores)</i>
<b>Particulars</b>	<b>Nine month period ended December 31, 2006</b>	<b>Full Year ended March 31, 2006</b>
<b><u>I. Cash Flow from Operating Activities</u></b>		
Net profit before tax	147	203
<b>Less/Add: non-cash items/ items required separately</b>		
Depreciation	47	30
Others	10	(2)
Changes in working capital and other provisions	(69)	(127)
Cash generated from operations	135	104
Tax paid (net of refunds)	(8)	(23)
<b>Net Cash provided by operating activities</b>	<b>127</b>	<b>81</b>
<b><u>II. Cash Flow from Investing Activities</u></b>		
Fixed Assets	(143)	(229)
Change in minority Interest	2	-
Interest / dividend received	3	5
Investments	(17)	135
<b>Net cash used for investing activities</b>	<b>(155)</b>	<b>(89)</b>
<b><u>III. Cash Flows from Financing Activities</u></b>		
Borrowings and other financing activities	36	5
<b>Net Cash provided/(used) for financing activities</b>	<b>36</b>	<b>5</b>
<b><u>IV. Net Change in Cash and Cash Equivalents (I+II+III)</u></b>		
	<b>7</b>	<b>(3)</b>
<b><u>V. Cash &amp; Cash Eq. at the beginning of the year</u></b>	<b>2</b>	<b>3</b>
<b><u>VI CASH AND CASH EQUIVALENTS OF THE ESOP TRUST ACQUIRED DURING THE YEAR</u></b>	<b>1</b>	<b>2</b>
<b><u>VII. Cash and Cash Eq. at the end of the year (IV+V+VI)</u></b>	<b>11</b>	<b>2</b>